ReviewJournal of bone and mineral metabolism2025
Sequential and combination therapy with romosozumab.
Review in Journal of bone and mineral metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture risk.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Preventing Hip (Proximal Femoral) Fractures: An Evidence-Based Review for Clinicians.Journal of clinical medicine · 2026Review
- Article
- Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.Aging clinical and experimental research · 2026Article
- Osteoporosis therapies and coronary risk: insights from vascular calcification biology and sclerostin signaling.Frontiers in endocrinology · 2026Review
- Case Report: Reopening the anabolic window - romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients.Frontiers in endocrinology · 2026Article
- Renal function predicts 12-month response to romosozumab readministration after denosumab in women with osteoporosis.Archives of osteoporosis · 2025Article
- Anabolic effects of Sost deficiency partially offset Opg deficiency-induced catabolism in cortical bone.Journal of bone and mineral metabolism · 2025Article
- Charcot foot disease: A new approach.Drugs & aging · 2025Review
- MIR155HG suppresses the osteogenic differentiation of bone marrow mesenchymal stem cells through regulating miR-155-5p and DKK1 expression.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of the bone-forming agent romosozumab has led to a dramatic improvement in osteoporosis treatment. While bisphosphonates remain the most commonly used drugs for the treatment of osteoporosis, it is recommended that patients at high risk of fractures initially receive bone-forming agents, followed by sequential treatment with bone resorption inhibitors. Romosozumab, an anti-sclerostin antibody, is an osteoporosis medication with both bone formation-stimulating and bone resorption-inhibiting properties, demonstrating significant efficacy in increasing bone mineral density and reducing fracture risk. However, due to the limited 12-month initial treatment period, sequential therapy with other osteoporosis medications is necessary following the completion of romosozumab administration. Due to the current lack of sufficient evidence regarding the use of romosozumab in sequential and combination therapies, this review aims to evaluate the efficacy of romosozumab as a sequential treatment, its effectiveness in combination with other agents, and its role in reducing new fragility fractures and increasing bone mineral density following sequential therapy after romosozumab. This review will summarize clinical trials and real-world data, providing valuable information to guide treatment decisions.
Indexed as
Identifiers
40024934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.